Direct identification of tumor-associated peptide antigens

Springer Seminars in Immunopathology

Volumn 18, Issue 2, 1996, Pages 171-183

  Engelhard, Victor H ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN;

ANTIGEN RECOGNITION; CYTOTOXIC T LYMPHOCYTE; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; HUMANS; PEPTIDES;

EID: 0029829956     PISSN: 03444325     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00820664     Document Type: Review

References (83)

1. Gross L (1943) Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res 3:326
2. Prehn RT, Main JM (1957) Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18:769
3. Old LJ, Boyse EA, Clarke DA, Carswell EA (1962) Antigenic properties of chemically-induced tumors. Ann NY Acad Sci 101:80
4. Hewitt H, Blake E, Walder A (1976) A critique of the evidence for active host defense against cancer based on personal studies of 27 murine tumors of spontaneous origin. Br J Cancer 33:241
5. Ward PL, Schreiber H (1991) MHC class I restricted T cells and immune surveillance against transplanted ultraviolet light-induced tumors. Semin Cancer Biol 2:321
6. Klarnet JP, Matis LA, Kern DE, Mizuno MT, Peace DJ, Thompson JA, Greenberg PD, Cheever MA (1987) Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory. J Immunol 138:4012
7. Van Pel A, Warnier G, Van den Eynde B, Lethe B, Lurquin C, Boon T (1991) Turn- antigens, TSTA, and T cell immune surveillance. Ann NY Acad Sci 636:43
8. Vanky F, Klein E (1982) Specificity of auto-tumor cytotoxicity exerted by fresh, activated and propagated human T lymphocytes. Int J Cancer 29:547
9. Vose BM, Bonnard GD (1982) Specific cytotoxicity against autologous tumour and proliferative responses of human lymphocytes grown in interleukin. Int J Cancer 29:33
10. Topalian SL, Rosenberg SA (1990) Tumor-infiltrating lymphocytes: evidence for specific immune reactions against growing cancers in mice and humans. Important Adv Oncol 1990:19
11. Slovin SF, Lackman RD, Ferrone S, Kiely PE, Mastrangelo MJ (1987) Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotypes, and specificity. J Immunol 137:3042
12. Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmuller G, Segurado OG (1993) Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 151:4209
13. Ioannides CG, Freedman RS, Platsoucas CD, Rashed S, Kim YP (1991) Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J Immunol 146:1700
14. Peoples GE, Schoof DD, Andrews JV, Goedegebuure PS, Eberlein TJ (1993) T-cell recognition of ovarian cancer. Surgery 114:227
15. Wolfel T, Herr W, Coulie P, Schmitt U, Meyer zum Buschenfelde KH, Knuth A (1993) Lysis of human pancreatic adenocarcinoma cells by autologous HLA class I-restricted cytolytic T-lymphocyte (CTL) clones. Int J Cancer 54:636
16. Yasumura S, Hirabayashi H, Schwartz DR, Toso JF, Johnson JT, Herberman RB, Whiteside TL (1993) Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck. Cancer Res 53:1461
17. Slingluff CL Jr, Cox AL, Stover JM Jr, Moore MM, Hunt DF, Engelhard VH (1994) Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68. Cancer Res 54:2731
18. Kannagi M, Sugamura K, Sato H, Okochi K, Uchino H, Hinuma Y (1983) Establishment of human cytotoxic T cell lines specific for human adult T cell leukemia virus-bearing cells. J Immunol 130:2942
19. Mitsuya H, Matis LA, Megeson M, Bunn PA, Murray C, Mann DL, Gallo RC, Broder S (1983) Generation of an HLA-restricted cytotoxic T cell line reactive against cultured tumor cells from a patient infected with human T cell leukemia/lymphoma virus. J Exp Med 158:994
20. Rickinson AB, Murray RJ, Brooks J, Griffin H, Moss DJ, Masucci MG (1992) T cell recognition of Epstein-Barr virus associated lymphomas. Cancer Surv 13:53
21. Nayersina R, Fowler P, Guilhot S, Missale G, Cerny A, Schlicht H-J, Vitiello A, Chesnut R, Person JL, Redeker AG, Chisari FV (1993) HLA-A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 150:4659
22. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, et al (1988) Use of tumor-infiltrating lymphocytes and interleukin 2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319:1676
23. Boon T, Cerottini JC, Van Pel A, Bruggen P van der (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337
24. Slingluff CL Jr, Cox AL, Henderson RA, Hunt DF, Engelhard VH (1993) Recognition of human melanoma cells by HLA-A2.1-restricted CTL is mediated by at least six shared peptide epitopes. J Immunol 150:2955
25. Storkus WJ, Zeh HJ 3rd, Maeurer MJ, Salter RD, Lotze MT (1993) Identification of human melanoma peptides recognized by class 1 restricted tumor infiltrating T lymphocytes. J Immunol 151:3719
26. Wolfel T, Klehmann E, Muller C, Schutt KH, Meyer zum Buschenfelde KH, Knuth A (1989) Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility antigen A2 as a restriction element for three different antigens. J Exp Med 170:797
27. Darrow TL, Slingluff CL, Siegler HF (1989) The role of class 1 MHC molecules in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes:evidence for shared tumor antigens. J Immunol 142:3329
28. Hom SS, Topalian SL, Simonis T, Mancini M, Rosenberg SA (1991) Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction. J Immunother 10:153
29. Peoples GE, Goedegebuure PS, Andrews JV, Schoof DD, Eberlein TJ (1993) HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol 151:5481
30. Yewdell JW, Bennink JR (1992) Cell biology of antigen processing and presentation to MHC class I molecule restricted T lymphocytes. Adv Immunol 52:1
31. Townsend AR, Öhlén C, Bastin J, Ljunggren H-G, Foster L, Karre K (1989) Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 340:443
32. Townsend A, Elliott T, Cerundolo V, Foster L, Barber B, Tse A (1990) Assembly of MHC class I molecules analyzed in vitro. Cell 62:285
33. Bodmer JG, Marsh SG, Albert ED, Bodmer WF, Dupont B, Erlich HA, Mach B, Mayr WR, Parham P, Sasazuki T, et al (1992) Nomenclature for factors of the HLA system, 1991. Hum Immunol 34:4
34. Engelhard VH (1994) Structure of peptides associated with MHC class I molecules. Curr Op Immunol 6:13
35. Engelhard VH (1994) Structure of peptides associated with class I and class II MHC molecules. Annu Rev Immunol 12:181
36. Lee SP, Thomas WA, Murray RJ, Khanim F, Kaur S, Young LS, Rowe M, Kurilla M, Rickinson AB (1993) HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol 67:7428
37. Bertoletti A, Chisari FV, Penna A, Guilhot S, Galati L, Missale G, Fowler P, Schlicht H, Vitiello A, Chesnut RC, Fiaccadori F, Ferrari C (1993) Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein. J Virol 67:2376
38. Bakker ABH, Schreurs MW, Boer AJ de, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG (1994) Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179:1005
39. Yoshino I, Goedegebuure PS, Peoples GE, Parikh AS, DiMaio JM, Lyerly HK, Gazdar AF, Eberlein TJ (1994) HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 54:3387
40. Ioannides CG, Fisk B, Fan D, Biddison WE, Wharton JT, O'Brian CA (1993) Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell Immunol 151:225
41. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, Melief CJ, Oseroff C, Yuan L, Ruppert J, Sidney J, Guericio MF del, Southwood S, Kubo RT, Chesnut RW, Grey H, Chisari FV (1994) The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 153:5586
42. Skipper J, Stauss HJ (1993) Identification of two cytotoxic T lymphocyte-recognized epitopes in the ras protein. J Exp Med 177:1493
43. Houbiers JG, Nijman HW, Burg SH van der, Drijfhout JW, Kenemans P, Velde CJ van de, Brand A, Momburg F, Kast WM, Melief CJ (1993) In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 23:2072
44. Elsas A van, Nijman HW, Van der Minne CE, Mourer JS, Kast WM, Melief CJ, Schrier PI (1995) Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201. Int J Cancer 61:389
45. Udaka K, Tsomides TJ, Eisen HN (1992) A naturally occurring peptide recognized by alloreactive CD8+ cytotoxic T lymphocytes in association with class I MHC protein. Cell 69:989
46. Mandelboim O, Berke G, Fridkin M, Feldman M, Eisenstein M, Eisenbach L (1994) CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369:67
47. Henderson RA, Cox AL, Sakaguchi K, Appella E, Shabanowitz J, Hunt DF, Engelhard VH (1993) Direct identification of an endogenous peptide recognized by multiple HLA-A2.1 specific cytotoxic T cells. Proc Natl Acad Sci USA 90:10275
48. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716
49. Haan JM den, Sherman NE, Blokland E, Huczko E, Koning F, Drijfhout JW, Skipper J, Shabanowitz J, Hunt DF, Engelhard VH, Goulmy E (1995) Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 268:1476
50. Wang W, Meadows LR, Haan JM den, Sherman NE, Chen Y, Blokland E, Shabanowitz J, Agulnik A, Hendrickson RC, Bishop CE, Hunt DF, Goulmy E, Engelhard VH (1995) Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 269:1588
51. Fossum B, Gedde-dahl T, Breivik J, Eriksen JA, Spurkland A, Thorsby E, Gaudernack G (1994) p21ras-peptide-specific T-cell responses in a patient with colrectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly→Asp). Int J Cancer 56:40
52. + cytotoxic T-cells. Cancer Res 53:3257
53. Yoshino I, Peoples GE, Goedegebuure PS, Maziarz R, Eberlein TJ (1994) Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J Immunol 152:2393
54. Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109
55. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92:432
56. Linehan DC, Peoples GE, Hess DT, Summerhayes IC, Parikh AS, Goedegebuure PS, Eberlein TJ (1995) In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour. Surg Oncol 4:41
57. Boon T, Coulie P, Marchand M, Weynants P, Wolfel T, Brichard V (1994) Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. Important Adv Oncol 1994:53
58. Traversari C, Bruggen P van der, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T (1992) A nonapeptide encoded by human MAGE-1 is recognized on HLA-A1 by cytotoxic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176:1453
59. Gaugler B, Van den Eynde B, Bruggen P van der, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T (1994) Human gene MAGE-3 codes for an antigen recognized on melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921
60. Bruggen P van der, Szikora JP, Boel P, Wildmann C, Somville M, Sensi M, Boon T (1994) Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur J Immunol 24:2134
61. Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, Bruggen P van der (1995) BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2:167
62. Zakut R, Topalian SL, Kawakami Y, Mancini M, Eliyahu S, Rosenberg SA (1993) Differential expression of MAGE-1,-2 and -3 messenger RNA in transformed and normal human cell lines. Cancer Res 53:5
63. Bruggen P van der, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643
64. Kawakami Y, Eliyahu S, Delgaldo CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA (1994) Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458
65. Celis E, Tsai V, Crimi C, DeMars R, Wentworth PA, Chesnut RW, Grey HM, Sette A, Serra HM (1994) Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 91:2105
66. Bruggen P van der, Bastin J, Gajewski T, Coulie PG, Boel P, Smet C de, Traversari C, Townsend A, Boon T (1994) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24:3038
67. Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Buschenfelde KHM zum, Boon T (1994) Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 24:759
68. Robbins PF, el-Gamil M, Kawakami Y, Stevens E, Yannelli JR, Rosenberg SA (1994) Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 54:3124
69. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961
70. Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA (1995) Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 181:799
71. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA (1994) Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J Exp Med 180:347
72. Castelli C, Storkus WJ, Maeurer MJ, Martin DM, Huang EC, Pramanik BN, Nagabhushan TL, Parmiani G, Lotze MT (1995) Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 181:363
73. Skipper JCA, Henndrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, Shabanowitz J, Wolfel T, Slingluff CL, Boon T, Hunt DF, Engelhard VH (1996) An HLA-A2 restricted tyrosinase antigen on melanoma cells results from post-translational modification and suggests a novel processing pathway for membrane proteins. J Exp Med 183:527
74. Brystryn J-C, Rigel D, Friedman RJ, Kopf A (1987) Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 123:1053
75. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB (1983) Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 9:689
76. Anichini A, Maccali C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G (1993) Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med 170:797
77. Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, Boon T (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 92:7976
78. Robbins PF, el-Gamil M, Li YF, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y, Rosenberg SA (1995) Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 154:5944
79. Bleiden TM, McAdam AJ, Frelinger JG, Lord EM (1991) Mechanism of cytolytic T lymphocyte killing of a low class I-expressing tumor. J Immunol 147:1433
80. Vegh Z, Wang P, Vanky F, Klein E (1993) Selectively down-regulated expression of major histocompatibility complex class I alleles in human solid tumors. Cancer Res 53:2416
81. Seung S, Urban JL, Schreiber H (1993) A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target. J Exp Med 178:933
82. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennink JR (1993) Identification of human cancers deficient in antigen processing. J Exp Med 177:265
83. Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM (1994) In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 179:1215